tirzepatide eating disorder Eli Lilly weight-loss drug appears to suppress binge-eating signal, small study finds Full article: Tirzepatide for overweight

The CARPREG II risk prediction index assigns points based on a number of different predictors including prior cardiac events or arrhythmias, baseline New York Heart Association Class III-IV or cyanosis, presence of a mechanical valve, ventricular dysfunction, high risk left-sided valve disease or left ventricular outflow tract obstruction, pulmonary hypertension, and coronary artery disease or high-risk aortopathies

By suppressing its release and hindering the production of glucose in the liver (a.k.a

Headache incidence peaked during dose escalation and declined significantly by week 8-12, demonstrating that this is an early-phase adaptation effect rather than a persistent problem throughout treatment

Allodynia appears among the top 50 adverse reactions reported for tirzepatide in the FAERS system